Form 4: Ionis Pharma EVP Sells 10,000 Shares Under 10b5-1 Plan
Insider Transaction Report
Ionis Pharmaceuticals' EVP, Chief Development Officer Richard S. Geary, sold 10,000 shares of common stock for approximately $50.37 per share under a pre-arranged trading plan.
Summary
- Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals, Inc. (IONS), reported the sale of 10,000 shares of common stock.
- The transaction occurred on September 2, 2025, at a weighted average price of $50.3671 per share.
- The shares were sold in multiple transactions with prices ranging from $50.01 to $50.92.
- This sale was executed pursuant to a Rule 10b5-1 Trading Plan adopted by Mr. Geary on May 6, 2025.
- Following the reported transaction, Mr. Geary beneficially owns 79,657 shares of Ionis Pharmaceuticals common stock directly.
Sentiment
Score: 5
Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan, which is generally considered a neutral event not indicative of new company performance or significant changes in executive sentiment.
Negatives
- An executive, Richard S. Geary, reduced his direct beneficial ownership in the company by 10,000 shares.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal impact on shareholder sentiment, as it is a pre-scheduled event rather than a reaction to new information.
Key Dates
| Date | Description |
|---|---|
| 05/06/2025 | Date the Rule 10b5-1 Trading Plan was adopted by Richard S. Geary. |
| 09/02/2025 | Date of the reported transaction (sale of common stock). |
| 09/04/2025 | Date the Form 4 filing was signed. |
Recommendation
holdThis Form 4 filing details a pre-scheduled insider stock sale under a 10b5-1 plan, which is a routine event for executives managing their personal finances. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this specific filing does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.
Keywords
IONIS PHARMACEUTICALS, IONS, Insider Trading, Form 4, Stock Sale, Executive Compensation, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.